Basic Information
| LncRNA/CircRNA Name | HCP5 |
| Synonyms | HLA complex P5 |
| Region | GRCh38_6:31400702-31477506 |
| Ensemble | ENSG00000206337 |
| Refseq | NR_040662 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blotting |
| Sample | The peripheral blood and bone marrow tissue samples,AML cell line SKM-1,AML193 cells |
| Expression Pattern | up-regulated |
| Function Description | HCP5 is highly expressed in AML and is positive associated with poor prognosis, and HCP5 knockdown was significantly suppressing AML cell line proliferation and inducing G1/S arrest in vitro. In mechanism, the proteasome subunit beta type 8 (PSMB8) expression was dramatically inhibited in HCP5 knockdown cells while increased in HCP5 overexpression cells.HCP5 regulates PI3K/AKT pathway activation depending on PSMB8. |
| Pubmed ID | 31836918 |
| Year | 2020 |
| Title | LncRNA HCP5 Promotes LAML Progression via PSMB8-mediated PI3K/AKT Pathway Activation |
External Links
| Links for HCP5 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |